
Supplementary Tables

S1.- Excluded studies

Author	Year	Reason for exclusion
De Lima A	2015	Intervention not relevant
Dominitz JA	2002	Outcome not relevant
Fonager K	1998	Outcome not relevant
Getahun D	2014	Outcome not relevant
Julsgaard M	2014	Outcome not relevant
Kornfeld D	1997	Intervention not relevant
Lin HC	2010	Intervention not relevant
Ludvigsson JF	2002	Intervention not relevant
Mahadevan U	2007	Intervention not relevant
Nguyen G	2009	Intervention not relevant
Oron G	2012	Outcome not relevant
Plauburg A	2016	Intervention not relevant
Puri A	2015	Intervention not relevant
Raatikainen K	2011	Intervention not relevant
Raatikainen K	2010	Outcome not relevant
Reddy D	2008	Outcome not relevant
Schnitzler F	2011	Intervention not relevant
Stefansson O	2010	Intervention not relevant
Piotr W	2015	Intervention not relevant
Norgard B	2000	Outcome not relevant
Norgard B	2007	Outcome not relevant
Langagergaad V	2007	Outcome not relevant

S2.- Quality Scores Studies

Author	Year	Ottawa classification		
		Selection	Comparability	Outcome
Bröms G ⁽¹⁹⁾	2014	****	**	***
Cleary BJ ⁽²³⁾	2009	***	*	**
Shim L ⁽²²⁾	2011	***	*	***
De Lima-Karagiannis A ⁽²¹⁾	2016	****	**	***
Moser MA ⁽⁶⁾	2000	***	**	**
Komoto S ⁽²⁵⁾	2016	***	*	**
Bortoli A ⁽⁷⁾	2011	***	*	***
Bush MC ⁽²⁰⁾	2004	***	*	***
Molnar T ⁽²⁸⁾	2010	**	**	***
Norgard B ⁽⁵⁾	2007	****	**	***
Norgard B ⁽¹⁰⁾	2003	****	*	***
Stephansson O ⁽²⁷⁾	2011	***	*	**
Bortlik M ⁽²⁴⁾	2013	****	**	***

S3- Summary of other treatments used in the thiopurine-exposed patients

Study	Thiopurine exposed patients		
Bröms ⁽¹⁹⁾	N/A		
Cleary ⁽²³⁾	2% 5-ASA	47% Steroids	7.6% Anti-TNF
Komoto ⁽²⁵⁾	N/A		
Norgard ⁽⁵⁾	N/A		
Shim ⁽²²⁾	68.4% 5-ASA	57.9% Steroids	-